Patents Examined by Chun W Dahle
  • Patent number: 11505585
    Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: November 22, 2022
    Assignees: argenx BV, The Board of Regents of the University of Texas System
    Inventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
  • Patent number: 11460470
    Abstract: The invention is directed to engineered Fc gamma receptor type III (Fc?II, HNA-1) polypeptides and use of these polypeptides to detect antibodies specific for human neutrophil antigens (HNA). The invention is also directed to methods for the diagnosing and determining susceptibility for developing Transfusion Reaction Acute Lung (TRALI).
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: October 4, 2022
    Assignee: One Lambda, Inc.
    Inventors: Jar-How Lee, Neng Jen Remi Shih, Julie Nguyen, Rui Pei
  • Patent number: 11447552
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: September 20, 2022
    Assignee: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Patent number: 11434295
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: September 6, 2022
    Assignee: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Patent number: 11427627
    Abstract: The present invention relates to variant Fc-containing molecules, such as antibodies and Fc-fusion molecules, having glycosylation characteristics favorable to largescale production of therapeutic molecules containing such variant Fc. Described herein are compositions and methods to improve glycosylation maturation of and to minimize the culture process-dependent effects of Fc-containing molecules, e.g., Fc-fusion molecules and antibodies. Creating single and multiple amino acid substitutions within the Fc domain with the aim to improve high mannose processing and glycosylation maturation.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: August 30, 2022
    Assignee: Amgen Inc.
    Inventors: Zhimei Du, Pranhitha Reddy, Randal B. Bass, Feng He, William C. Fanslow, III, Yuling Zhang, Da Ren, Randal R. Ketchem
  • Patent number: 11421022
    Abstract: Herein is reported a method for producing an antibody Fc-region conjugate comprising as first component an antibody Fc-region and as second component at least one binding entity that specifically binds to a target using a transpeptidase for enzymatic conjugation of the antibody Fc-region to at least one binding entity.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: August 23, 2022
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Sebastian Fenn, Erhard Kopetzki
  • Patent number: 11414493
    Abstract: The present disclosure relates to a polypeptide containing an Fc domain in which a part of an amino acid sequence of a human antibody Fc domain is substituted with another amino acid sequence, or an aglycosylated antibody containing the same. The Fc domain of the present disclosure is optimized by substituting a part of an amino acid sequence of a wild-type Fc domain with another amino acid sequence. Therefore, it is useful in treatment of cancer due to superior selective binding ability to Fc?RIIIa among Fc receptors, and can be prepared as a homogeneous aglycosylated antibody through bacterial culture.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: August 16, 2022
    Assignee: KOOKMIN UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION
    Inventors: Sang Taek Jung, Migyeong Jo
  • Patent number: 11384149
    Abstract: The present invention is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain (“bi-specific monovalent Fc diabodies”) and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of CD32B and one binding site specific for an epitope of CD79b (i.e., a “CD32B×CD79b bi-specific monovalent Fc diabody”). The bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to CD32B and CD79b. The invention is directed to such compositions, to pharmaceutical compositions that contain such bi-specific monovalent Fc diabodies and to methods for their use in the treatment of inflammatory diseases or conditions, and in particular, systemic lupus erythematosus (SLE) and graft vs. host disease.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: July 12, 2022
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang, Kalpana Shah, Ezio Bonvini, Paul A. Moore, Wei Chen
  • Patent number: 11384148
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: July 12, 2022
    Inventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold
  • Patent number: 11359014
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-5 protein, e.g., human Siglec-5 or a mammalian Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: June 14, 2022
    Assignee: Alector LLC
    Inventors: Kate Monroe, Helen Lam, Patricia Culp, Arnon Rosenthal
  • Patent number: 11352414
    Abstract: The invention relates to multimeric fusion proteins which bind to human Fc receptors. The invention also relates to therapeutic compositions comprising the proteins, and their use in the treatment of immune disorders.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: June 7, 2022
    Inventors: Farnaz Fallah-Arani, Robert Anthony Griffin, David Paul Humphreys, Shirley Jane Peters, Bryan John Smith, Paul Edward Stephens
  • Patent number: 11352444
    Abstract: The invention provides non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing transgenic cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits. Certain aspects of the invention also relate to diagnostic and treatment methods using the antibodies of the invention.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: June 7, 2022
    Assignee: ABLEXIS, LLC
    Inventors: Larry Green, Hiroaki Shizuya
  • Patent number: 11352431
    Abstract: The invention provides anti-FcRH5 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: June 7, 2022
    Assignee: Genentech, Inc.
    Inventors: Allen J. Ebens, Meredith C. Hazen, Jo-Anne Hongo, Jennifer W. Johnston, Teemu T. Junttila, Ji Li, Andrew G. Polson
  • Patent number: 11332538
    Abstract: Methods and compositions involving polypeptides having an aglycosylated antibody Fc domain are provided. In certain embodiments, polypeptides have an aglycosylated Fc domain that contains one or more substitutions compared to a native Fc domain. Additionally, some embodiments involve an Fc domain that is binds some Fc receptors but not others. For example, polypeptides are provided with an aglycosylated Fc domain that selectively binds C1q, and optionally activating Fc receptors, but that is significantly reduced for binding to the inhibitory Fc?RIIb receptor. Furthermore, methods and compositions are provided for promoting complement dependent cytotoxicity (CDC) using a polypeptide having a modified aglycosylated Fc domain and a second non-Fc binding domain, which can be an antigen binding region of an antibody or a non-antigen binding region. Some embodiments concern antibodies with such polypeptides, which may have the same or a different non-Fc binding domain.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: May 17, 2022
    Assignee: Research Development Foundation
    Inventors: George Georgiou, Chang-Han Lee
  • Patent number: 11332528
    Abstract: The present invention provides anti-CEACAM1 antibodies with improved binding abilities specific to CEACAM1, and a use thereof. Anti-CEACAM1 antibodies according to the present invention exhibit superior binding abilities specific to CEACAM1, and also activate the anti-cancer immune functions of cytotoxic T cells and natural killer cells, and thus, each one of them can be effectively used as an anti-cancer agent and a composition for treating cancer.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: May 17, 2022
    Assignees: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, GREEN CROSS CORPORATION
    Inventors: So-Young Eun, Miyoung Oh, Hye-Young Park, Mijung Lee, Aerin Yoon, Hye In Yum, Hyemi Nam, Eunhee Lee, Jongwha Won
  • Patent number: 11319383
    Abstract: The present invention relates to compositions and methods for antibody-mediated therapy. In particular, provided herein are engineered immunoglobulins with altered half-life.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: May 3, 2022
    Assignee: Universitetet | Oslo
    Inventors: Jan Terje Andersen, Stian Foss, Inger Sandlie
  • Patent number: 11306297
    Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: April 19, 2022
    Assignee: University of Washington
    Inventors: Jeffrey A. Ledbetter, Martha Hayden-Ledbetter, Keith Elkon, Xizhang Sun
  • Patent number: 11286300
    Abstract: Herein is reported an antibody that specifically binds to human CD 19, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 20 or 28, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 07, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 08, as well as methods of using the same.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: March 29, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Claudia Ferrara Koller, Guy Georges, Alexander Haas, Hubert Kettenberger, Ekkehard Moessner, Tilman Schlothauer, Michael Molhoj, Laurent Lariviere
  • Patent number: 11266744
    Abstract: Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: March 8, 2022
    Assignee: AMGEN INC.
    Inventors: Colin V. Gegg, Kenneth W. Walker, Leslie P. Miranda, Fei Xiong
  • Patent number: 11267868
    Abstract: A polypeptide containing an antibody Fc region variant which has an amino acid sequence in which an amino acid alteration at position 238 according to EU numbering is combined with other specific amino acid alteration(s), was found to have decreased binding activities to all activating Fc?Rs, in particular Fc?RIIa (R type), while maintaining its Fc?RIIb-binding activity, when compared to a polypeptide containing a native IgG Fc region.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: March 8, 2022
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Futa Mimoto, Hitoshi Katada, Tomoyuki Igawa